newsfilter
← Latest News
GlobeNewswire·

TCR² Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

- gavo-cel Phase 1 trial dataset anticipated in September 2022- Initial TC-510 Phase 1 data anticipated in 2H 2022 - Expansion of manufacturing capacity and commencement of gavo-cel clinical trial material production at ElevateBio BaseCamp CAMBRIDGE,